Pharming Group (NASDAQ:PHAR - Get Free Report)'s share price shot up 6.6% during trading on Monday . The company traded as high as $9.10 and last traded at $9.25. 100 shares traded hands during trading, a decline of 98% from the average session volume of 5,540 shares. The stock had previously closed at $8.68.
Wall Street Analyst Weigh In
Several brokerages have weighed in on PHAR. Jefferies Financial Group initiated coverage on Pharming Group in a report on Monday, December 9th. They issued a "buy" rating and a $14.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a research note on Tuesday, December 17th.
View Our Latest Analysis on PHAR
Pharming Group Stock Performance
The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53. The stock has a market cap of $573.16 million, a price-to-earnings ratio of -32.40 and a beta of -0.10. The stock has a fifty day simple moving average of $9.21 and a two-hundred day simple moving average of $8.56.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its stake in Pharming Group (NASDAQ:PHAR - Free Report) by 16.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 47,997 shares of the company's stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 at the end of the most recent quarter. 0.03% of the stock is owned by hedge funds and other institutional investors.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
